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TRAIL Mediates Liver Injury by the Innate Immune System in the
Bile Duct–Ligated Mouse
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Justin L. Mott1, Yuko Akazawa1, Howard C. Masuoka1, Charles L. Howe3, and Gregory J.
Gores1
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Mayo Clinic, Rochester, MN
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The contribution of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a death ligand
expressed by cells of the innate immune system, to cholestatic liver injury has not been explored.
Our aim was to ascertain if TRAIL contributes to liver injury in the bile duct–ligated (BDL) mouse.
C57/BL6 wild-type (wt), TRAIL heterozygote (TRAIL+/í), and TRAIL knockout (TRAILí/í) mice
were used for these studies. Liver injury and fibrosis were examined 7 and 14 days after BDL,
respectively. Hepatic TRAIL messenger RNA(mRNA) was 6-fold greater in BDL animals versus
sham-operated wt animals (P < 0.01). The increased hepatic TRAIL expression was accompanied
by an increase in liver accumulation of natural killer 1.1 (NK 1.1)–positive NK and natural killer T
(NKT) cells, the predominant cell types expressing TRAIL. Depletion of NK 1.1–positive cells
reduced hepatic TRAIL mRNA expression and serum alanine aminotransferase (ALT) values.
Consistent with a role for NK/NKT cells in this model of liver injury, stress ligands necessary for
their recognition of target cells were also up-regulated in hepatocytes following BDL. Compared to
sham-operated wt mice, BDL mice displayed a 13-fold increase in terminal deoxynucleotidyl
transferase–mediated dUTP nick-end labeling (TUNEL) and an 11-fold increase in caspase 3/7–
positive hepatocytes (P < 0.01). The number of TUNEL and caspase 3/7–positive cells was reduced
by >80% in BDL TRAIL knockout animals (P < 0.05). Likewise, liver histology, number of bile
infarcts, serum ALT values, hepatic fibrosis, and animal survival were also improved in BDL
TRAILí/í animals as compared to wt animals.
Conclusion—These observations support a pivotal role for TRAIL in cholestatic liver injury
mediated by NK 1.1–positive NK/NKT cells.
Cholestasis, defined as an impairment in bile formation, is a common syndrome in clinical
practice. For example, cholestasis is a prominent feature of biliary atresia, primary sclerosing
cholangitis, primary biliary cirrhosis, and other forms of chronic biliary tract disease.1–3 The
retention of bile acids normally excreted into bile within the liver elicits a toxic response,
especially hepatocyte injury. This cell-specific injury rapidly results in secondary activation
of hepatic resident macrophages, Kupffer cells, and recruitment of other inflammatory cells
into the liver, including neutrophils4,5; these cell types are all cellular components of the innate
immune system.6 This more generalized phase of injury by the innate immune system promotes
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hepatic fibrosis, which leads to cirrhosis and sequelae of chronic liver failure. Currently,
therapeutic options for the treatment of cholestatic liver injury are limited. Rational therapeutic
strategies to reduce hepatic injury during cholestasis will be predicated upon a better
understanding of the mechanisms of liver injury. Thus, further insight into the cellular
mechanisms by which cholestasis causes hepatocyte injury is of biomedical and clinical
importance.
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Hepatocyte damage in human liver diseases commonly occurs by apoptosis.7 Although
apoptosis can be induced by a wide variety of stimuli and mechanisms, the hepatocyte is
particularly susceptible to apoptosis by death receptors.8 For example, mice deficient in Fas
have reduced liver injury and hepatic fibrosis following bile duct ligation (BDL), a rodent
model of cholestasis.9,10 Bile acids also stimulate expression of another death receptor termed
tumor necrosis factor–related apoptosis-inducing ligand receptor 2 (TRAIL-R2), which is also
called death receptor 5 (DR5).11 When engaged by its cognate ligand tumor necrosis factor–
related apoptosis-inducing ligand (TRAIL), this receptor also induces apoptosis by
mechanisms analogous to Fas signaling.12 Although TRAIL is not thought to induce cell death
of normal hepatocytes, it does cause apoptosis of virally infected, transformed cells and fatty
acid–treated hepatocytes.13–16 More importantly, TRAIL has been shown to potentiate
cytotoxic Fas signaling in the liver.17 TRAIL enhances Fas-mediated hepatotoxicity by
inducing sustained activation of c-Jun-N-terminal kinase (JNK), a member of the mitogenactivated protein kinase family that contributes to many forms of liver injury.18 Thus, TRAIL
activation synergistically augments Fas-mediated hepatotoxicity, a mechanism of liver injury
potentially relevant to cholestatic liver damage. Despite this potential synergistic toxicity, the
role of TRAIL in cholestatic liver injury has not been explored.
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The ligands for death receptors are expressed predominantly by cells of the innate and adaptive
immune system. Indeed, TRAIL itself is expressed by cells of the innate immune system,
especially natural killer (NK) cells, natural killer T (NKT) cells, and monocytes.19 We have
previously examined TRAIL expression by Kupffer cells in the BDL mouse liver.20 TRAIL
expression by Kupffer cells was minimal as compared to their expression of the other death
ligands, tumor necrosis factor Į and Fas ligand. However, TRAIL expression by NK/NKT cells
and the contribution of these cell types to liver injury in this model have not been explored.
Given the importance of NK/NKT cells in other forms of liver injury, their potential
contribution to hepatocyte apoptosis, liver injury, and fibrosis warrants further study.21 If NK
cells are to contribute to cholestatic liver injury of hepatocytes, they would need a recognition
system. NK cells recognize target cells, in part, by the cytotoxic natural killer group 2 member
D receptor, which binds glycoprotein stress ligands.22 The murine stress ligands include H60,
murine UL16-binding protein-like transcript 1 (MULT-1), and retinoic acid early inducible
gene 1Į (RAE-1Į), RAE-1ȕ, RAE-1Ȗ, RAE-1į, and RAE-1İ.22 Of these stress ligands, H60
is the most abundantly expressed in many forms of injury.23
The overall objective of this study was to determine if NK/NKT cells contribute to liver injury
by a TRAIL-dependent mechanism. To address this subject, we examined the role of NK/NKT
cells in cholestatic liver injury and employed BDL wild-type (wt), TRAIL heterozygote
(TRAIL+/í), and TRAIL homozygote (TRAILí/í) mice. The results of this study support a
critical role for TRAIL in cholestatic liver injury by the innate immune system.

Materials and Methods
Animal Models
The care and use of the animals for these studies were reviewed and approved by the
Institutional Animal Care and Use Committee at the Mayo Clinic. C57/BL6 wt, TRAIL+/í,
and TRAILí/í mice (6–8 weeks of age, 20–25 g body weight) were employed for these studies.
Hepatology. Author manuscript; available in PMC 2008 October 20.
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The TRAIL+/í and TRAILí/í mice were obtained from Taconic Farm, Inc. (Hudson, NY) via
an agreement with Amgen, Inc. (Thousand Oaks, CA).24,25 Mice were maintained in a
temperature-controlled (22°C), pathogen-free environment and fed a standard rodent chow diet
and water ad libitum. For experimental procedures, mice were anesthetized with ketamine (60
mg/kg of body weight) plus xylazine (10 mg/kg of body weight) by intraperitoneal injection.
After a midline upper-abdominal incision, the peritoneal cavity was opened, the abdominal
wall was retracted, and the common hepatic bile duct was double-ligated and divided between
the ligatures as previously described by us in detail.9 Sham-operated wt mice, used as controls,
under-went laparotomy with exposure but no ligation of the common bile duct. The fascia and
skin of the midline abdominal incision were closed with sterile surgical 5–0 sutures
(ETHICON, Inc., Somerville, NJ). After 3, 7, or 14 days of BDL, depending on the
experimental procedures, mice were reanesthetized, and blood was obtained from the vena
cava inferior for serum alanine aminotransferase (ALT), total bilirubin, and bile acid (total bile
acid colorimetric assay kit, Bio-Quant, Inc., San Diego, CA) determinations26 prior to liver
tissue being procured for additional studies (vide infra). As both NK and NKT cells express
the cell marker NK 1.1, we will refer to these cell populations collectively as NK 1.1–positive
NK/NKT cells. To investigate the role of hepatic NK 1.1–positive NK/NKT cells and TRAIL
during cholestasis, wt mice were bile duct–ligated for 7 days with or without the depletion of
NK 1.1–positive cells by intraperitoneal injection of either a specific anti-NK 1.1 monoclonal
antibody (PK 136, BD Bioscience, San Jose, CA; 250 µg on days í1, 3, and 7 post-BDL) or
a nonspecific immunoglobulin G (IgG) isotype–matched monoclonal antibody (JIE7-c,
Developmental Studies Hybridoma Bank, University of Iowa) under similar conditions.27 In
all models of liver injury, the liver was removed and cut into small pieces and either snapfrozen in liquid nitrogen for storage at í80°C or fixed in freshly prepared 4% paraformaldehyde
in phosphate-buffered saline for 24 hours at 4°C. Liver sections were also subjected to RNA
extraction using the TRIzol reagent (Invitrogen, Carlsbad, CA).
Histopathology
For histological review of hematoxylin and eosin (H&E)–stained liver sections by light
microscopy (Eclipse Meta Morph V 5.0.7, Nikon, West Lafayette, IN), the liver was diced into
5 mm × 5 mm sections, fixed in 4% paraformaldehyde for 48 hours, and then embedded in
paraffin. Tissue sections (4 µm) were prepared using a microtome (Reichert Scientific
Instruments, Buffalo, NY) and placed on glass slides. H&E staining was performed according
to standard techniques.
Terminal Deoxynucleotidyl Transferase–Mediated dUTP Nick-End Labeling (TUNEL) Assay,
Immunofluorescent Identification of Activated Caspases 3/7, and Cellular Colocalization of
Cathepsin B and Lysosome-Associated Membrane Protein 1 (LAMP-1)
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Apoptotic cells were quantitated by the TUNEL assay, which enzymatically labels free 3ƍ-OH
ends of damaged DNA with a fiuorescently labeled nucleotide as we have previously described
in detail.28 TUNEL-labeled cells (that is, fluorescent nuclei) were quantified by the number
of positive cells per high-power field being counted. A total of 10 high-power fields were
analyzed for each animal with excitation and emission wavelengths of 380 and 430 nm,
respectively, using an inverted laser scanning confocal microscope (LSM 510, Carl Zeiss
Micro-Imaging, Inc., Thornwood, NJ) equipped with a 40X NA 1.4 lens and LSM 510 imaging
software. Data were expressed as the number of TUNEL-positive cells per 10 high-power
fields. Immunofluorescence analysis for activated caspases 3/7 was performed using a rabbit
anti-active caspase 3/7 polyclonal antibody (BD Biosciences/Pharmingen, San Diego, CA)
recognizing a common neoepitope shared by activated caspases 3 and 7 as we have previously
described.28 The liver specimens were viewed by confocal microscopy using excitation and
emission wavelengths of 351 and 364 nm, respectively. The number of caspase 3/7–positive
cells was quantified per 10 high-power fields as described above for the TUNEL assay.
Hepatology. Author manuscript; available in PMC 2008 October 20.
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Immunofluorescence analysis for cathepsin B was also performed as previously described by
us.29 Cellular localization of cathepsin B was demonstrated using colocalization with the
lysosome marker LAMP-1 (H-228, Santa Cruz, Santa Cruz, CA). Liver specimens were viewed
by confocal microscopy for cathepsin B (488 and 507 nm) and LAMP-1 (577 and 590 nm),
respectively. Hepatocytes were scored according to their diffuse versus punctate fluorescent
pattern per 10 high-power fields. Data were expressed as percent diffuse of total hepatocytes
scored. Negative control slides were incubated with non-immune immunoglobulin for both the
caspase 3/7 and cathepsin B/LAMP-1 immunohistochemistry.
Identification of Hepatic NK and NKT Cells by Immunohistochemistry
The tissue sections were pre-incubated with Block-ace (Dako Cytomation, Inc., Carpinteria,
CA) for 10 minutes at 37°C to block nonspecific binding of the primary antibody. Endogenous
peroxidise activity was blocked with 0.3% H2O2 and 0.1% NaN3 in distilled water for 10
minutes at room temperature. The sections were then incubated with 1:500 diluted biotinconjugated anti-NK 1.1 mouse primary antibody (BD Bioscience) overnight, rinsed three times
with phosphate-buffered saline, and then incubated with avidin-biotin peroxidase complexes
(Vector Laboratories, Burlingame, CA). Histochemical development was achieved with a
commercial 3,3ƍ-diaminobenzidine (DAB) substrate kit (Vector Laboratories). Finally, the
sections were counterstained for 3 minutes with hematoxylin and coverslipped with mounting
medium for light microscopy.
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Isolation of Mouse Hepatocytes
Mouse hepatocytes were isolated by collagenase perfusion through the hepatic portal vein as
described previously.30 Mouse hepatocytes were purified by Percoll gradient
centrifugation31; average viability by trypan blue exclusion was 90%.
Quantitative Real Time–Polymerase Chain Reaction (rt-PCR)
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Total RNA was isolated from liver tissue using the TRIzol Reagent (Invitrogen). For each RNA
sample, a 10-µg aliquot was reverse-transcribed into complementary DNA (cDNA) using an
oligo-dT random primer and Maloney murine leukemia virus reverse transcriptase (Invitrogen)
as previously described in detail.32 After the reverse transcription reaction, the cDNA template
was amplified by rt-PCR with Taq DNA polymerase (Invitrogen) using standard protocols.
All amplified polymerase chain reaction (PCR) products were confirmed by electrophoresis
in 1% low–melting temperature agarose gel, stained with ethidium bromide, and photographed
using ultraviolet illumination. The expected base pair (bp) PCR products were identified, and
the bands were cut from the gel. Next, PCR products were eluted into
trishydroxymethylaminomethane (Tris)-HCl using a DNA elution kit (Qiagen, Valencia, CA).
The concentration of DNA in the extracted PCR product was measured spectrophotometrically
(DU 4400, Beckman, Palo Alto, CA) as copies per milliliter at 260 nm. Extracted PCR products
were prepared as standards at concentrations of 1010, 109, 108, 107, 106, 105, 104, 103, and
102 copies/µL. For quantification studies, quantitative rt-PCR was performed using the Light
Cycler (Roche Diagnostics Corp., Mannheim, Germany) and SYBR green as the fluorophore
(Invitrogen). The inverse linear relationship between copy number and cycle number was then
determined. This standard curve was used to calculate the copy number in the experimental
sample. The copy number of messenger RNA (mRNA) in each sample was expressed as a
relative ratio of product copies per milliliter to copies per milliliter of housekeeping gene 18S
from the same RNA (respective cDNA) sample and PCR run.11 PCR primers (all obtained
from the Mayo DNA Synthesis Core Facility, Rochester, MN) were as follows: TRAIL-R2/
DR5 forward 5ƍ-TGA CGG GGA AGA GGA ACT GA-3ƍ and reverse 5ƍ-GGC TTT GAC CAT
TTG GAT TTG A-3ƍ (yielding a 389-bp product), TRAIL forward 5ƍ-CCC TGC TTG CAG
GTT AAG AG-3ƍ and reverse 5ƍ-GGC CTA AGG TCT TTC CAT CC-3ƍ (yielding a 240-bp
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Kahraman et al.

Page 5

NIH-PA Author Manuscript

product), Į-smooth muscle actin (Į-SMA) forward 5ƍ-ACT ACT GCC GAG CGT GAG AT-3ƍ
and reverse 5ƍ-AAG GTA GAC AGC GAA GCC AG-3ƍ (yielding a 452-bp product), collagen
1Į (I) forward 5ƍ-GAA ACC CGAGGTATG CTT GA-3ƍ and reverse 5ƍ-GAC CAG GAG GAC
CAG GAA GT-3ƍ (yielding a 276-bp product), and finally NK 1.1 forward 5ƍ-TCA TCC TCC
TTG TCC TGA CC-3ƍ and reverse 5ƍ-TTG AAT GAG CAG CAA AGT GG-3ƍ (yielding a
248-bp product). For quantitative rt-PCR of the stress ligands, the Light Cycler Taq Man Master
kit and universal probes (Roche Diagnostics Corp., Indianapolis, IN) were used.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers were employed to normalize
the samples. PCR primers, also obtained from the Mayo DNA Synthesis Core Facility, were
as follows: GAPDH forward 5ƍ-AGC TTG TCA TCA ACG GGA AG-3ƍ and reverse 5ƍ-TTT
GAT GTT AGT GGG GTC TCG-3ƍ (yielding a 240-bp product), H60 forward 5ƍ-ACA GCA
TAG CAT CTA CTT TTA TCC AC-3ƍ and reverse 5ƍ-TCC ATG GCA CTG CTG TTA TC-3ƍ
(yielding a 299-bp product), MULT-1 forward 5ƍ-CAT GCC ATT GGT GCT CAT AG-3ƍ and
reverse 5ƍ-TGC TTG TGT CAA CAC GGA AT-3ƍ (yielding a 250-bp product), and finally
pan-RAE-1 forward 5ƍ-TGG ACA CTC ACA AGA CCA ATG-3ƍ and reverse 5ƍ-CCC AGG
TGG CAC TAG GAG T-3ƍ (yielding a 75-bp product).
Immunoblot Analysis
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Liver tissue was directly lysed for 30 minutes on ice with a lysis buffer consisting of 50 mM/
L Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM
ethylene diamine tetraacetic acid, 1mM phenylmethylsulfonyl fluoride, 1 µg/mol aprotinin, 1
µg/mol leupeptin, 1 µg/mol pepstatin, 1 M Na3VO4, and 1 mM NaF. After centrifugation at
13,000g for 15 minutes at 4°C, the protein concentration in the supernatant was measured using
Bradford’s reagent (Bio-Rad, Hercules, CA). The supernatant protein was denatured by boiling
for 10 minutes in distilled water. Protein (50 µg) was resolved by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDSPAGE) on a gradient gel and then transferred onto
nitrocellulose membranes. Blocking was carried out using 5% nonfat dairy milk in Trisbuffered saline (20 mM Tris, 150 mM NaCl, pH 7.4) with 0.1% Tween-20 for 1 hour at room
temperature. Primary antibodies were diluted 1:1000 in a blocking solution and incubated
overnight at 4°C. The following antibodies were used: anti-Bak (TC-102, mouse monoclonal
antibody, Calbiochem, San Diego, CA), anti-FLIP (rabbit polyclonal IgG, Upstate
Biotechnology, Lake Placid, NY), Bax (N-20, rabbit polyclonal IgG, Santa Cruz), Bcl-XL
(H-62, rabbit polyclonal IgG, Santa Cruz), Bid (M-20, goat polyclonal IgG, Santa Cruz), Bim
(rat monoclonal antibody, Chemicon, Australia), Fas (X-20 G, goat polyclonal IgG, Santa
Cruz), Fas-L (N-20, rabbit polyclonal antibody, Santa Cruz), Mcl-1 (rabbit anti-mouse Ab,
Rockland, Gilbertsville, PA), and Ȗ-Tubulin (mouse monoclonal antibody, Sigma-Aldrich
Corp., St. Louis, MO). To detect antigenantibody complexes, peroxidise-conjugated secondary
antibodies (Biosource International, Camarillo, CA) were diluted 1:3000 in a blocking solution
and incubated for 45 minutes at room temperature. Immune complexes were visualized using
chemiluminescent substrate (Amersham, IL) and Kodak X-OMAT film (Eastman Kodak,
Rochester, NY) according to the manufacturer’s instructions.
Immunohistochemistry for Į-SMA and Determination of Liver Fibrosis by Sirius Red Staining
The sections were stained for Į-SMA using amouse monoclonal antibody (NeoMarkers,
Fremont, CA), which was prediluted in 0.05 mol/L Tris-HCl, pH 7.6, containing stabilizing
protein and 0.015 mol/L sodium azide by the manufacturer for staining formalin-fixed,
paraffin-embedded tissues. The sections were incubated with the primary antibody overnight
at 4°C in a 1:200 dilution. Negative control slides were incubated with nonimmune
immunoglobulin under the same conditions. Secondary reagents were obtained from the Dako
Cytomation En Vision + System-HRP ready-to-use kit; DAB chromogen solution was used
for visualization by light microscopy. Finally, the tissue was counterstained with hematoxylin
for 3 minutes. Liver fibrosis was quantified using Sirius red staining as described by Arteel et
Hepatology. Author manuscript; available in PMC 2008 October 20.
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al.33 Direct red 80 and Fast-green FCF (color index 42053) were obtained from Sigma-Aldrich
Diagnostics. Liver sections were stained, and red-stained collagen fibers were quantified by
digital image analysis as previously described by us in detail.26
Statistical Analysis
All data represent at least five separate experiments and are expressed as the mean ± standard
error unless otherwise indicated. Differences between groups were compared using analysis
of variance (ANOVA) for repeated measures and the post hoc Bonferroni test to correct for
multiple comparisons. A P value less than 0.05 was considered to be statistically significant.
All statistical analyses were performed using In-Stat Software (Graph Pad, San Diego, CA).

Results
Hepatic NK and NKT Cells Are Increased in the BDL Mouse and Contribute to Liver Injury
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Initially, we sought to examine the role of NK/NKT cells in murine liver following BDL. To
address this question, we performed immunohistochemistry for these cell types in the liver
using antisera specific for the NK/NKT cell marker NK 1.1.27 An increase in these cell types
was observed in the BDL liver regardless of the mouse genotype—wt, TRAIL+/í, or
TRAILí/í (Fig. 1A). Likewise, quantitative rt-PCR also demonstrated increased but similar
mRNA expression levels for NK 1.1 in the liver of all three genotypes following BDL (Fig.
1B). In an additional study, wt mice following BDL for 7 days were treated either with a specific
anti-NK 1.1 antibody or with a nonspecific, IgG isotype–specific, monoclonal antibody. As
previously reported, 27 treatment of mice with the anti-NK 1.1 antibody, but not the nonspecific
control antibody, markedly reduces the number ofNK1.1–positive cells in the liver (Fig. 1C).
Consistent with the immunohistochemistry data, quantitative rt-PCR also demonstrated
decreased mRNA expression levels for NK 1.1 in the livers of anti-NK 1.1–treated BDL wt
mice versus control IgG-treated BDL wt mice (Fig. 1D). Histopathological examination of
liver specimens from 7-day BDL wt mice demonstrated severe cholestatic hepatitis with
widespread bile infarctions (confluent foci of feathery hepatocyte degeneration, a pathognomic
feature of large bile duct obstruction; Fig. 2A), bile ductular proliferation, portal edema, and
hepatocellular damage. Liver damage was markedly reduced in specimens from BDL wt
animals upon treatment with the anti-NK 1.1 antibody. In addition, bile infarctions were also
less evident in BDL wt mice treated with the anti-NK 1.1 antibody than in BDL wt mice treated
with control, isotype-identical IgG (Fig. 2A). Determination of serum ALT values resulted in
a significant decrease in BDL wt mice after depletion of NK 1.1–positive cells (Fig. 2B). NK
1.1–positive NK/NKT cells induce liver injury by recognition of stress ligands on target cells.
22 To further implicate these cells in liver injury following BDL, hepatic mRNA expression
of the stress ligands—H60, MULT-1, and pan-RAE-1—was quantified in hepatocytes. Indeed,
4–6-, and 7-fold increases in expression of H60, MULT-1, and pan-RAE-1, respectively, were
identified in hepatocytes of 3-day BDL wt mice versus sham-operated control mice (Fig. 3).
Taken together, these observations demonstrate an increase in NK 1.1–positive NK/NKT cells
as well as a preferential up-regulation of these stress ligands in the liver following BDL and
implicate a role for these cells in this model of liver injury.
NK/NKT Cells Are the Predominant Source of TRAIL in the BDL Liver
Next, we ascertained if hepatic tissue TRAIL mRNA was increased following BDL. Indeed,
after 7 days of BDL, a 6-fold significant increase in TRAIL mRNA was observed in wt animals
as compared to sham-operated controls (6.8 ± 0.7 versus 1 ± 0.2 TRAIL/18S mRNA ratio, P
< 0.01). Hepatic tissue TRAIL mRNA levels were significantly decreased in BDL wt mice
after depletion of NK 1.1–positive cells (Fig. 4). These data indicate an increase in hepatic
TRAIL expression due to an accumulation of NK 1.1–positive NK/ NKT cells in the BDL
liver. However, this accumulation is not TRAIL-dependent.
Hepatology. Author manuscript; available in PMC 2008 October 20.
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The above studies demonstrate that NK 1.1–positive NK/NKT cells contribute to cholestatic
liver injury. Also, these cells are the source of increased TRAIL in the BDL liver. Next, we
sought to determine if liver injury by these cells was TRAIL-dependent. Before embarking on
a series of studies assessing apoptosis and liver injury in genetic models of BDL, we provided
assurance that protein expression of apoptosis effectors was similar between both genotypes.
Immunoblot analysis was performed for several apoptosis effector proteins including Fas, Bax,
Bak, Bim, c-FLIP, Bid, Bcl-XL, and Mcl-1 (Fig. 5A). Hepatic protein levels for these key
apoptotic effectors were similar between wt and TRAIL-deficient mice under basal conditions.
As TRAIL can enhance Fas-mediated hepatotoxicity and Fas plays a role in hepatic injury
during BDL,26 further immunoblot analyses for the Fas receptor and ligand were performed.
As demonstrated (Fig. 5B), no alterations in the expression levels of the Fas receptor and ligand
were observed in wt, TRAIL+/í, and TRAILí/í mice following BDL.
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Next, to examine the effects of TRAIL in mediating hepatic apoptosis, wt, TRAIL+/í, and
TRAILí/í mice were subjected to BDL for 7 days. Liver histopathology from wt animals
demonstrated numerous clusters of apoptotic cells in a background of altered hepatic microarchitecture (Fig. 6A). Quantitation of these TUNEL-positive cells demonstrated a 13-fold
increase in wt BDL mice compared to sham-operated controls. Consistent with an allelic dose
effect, the number of TUNEL-positive cells observed in TRAIL+/í mice was intermediate
between wt and TRAILí/í BDL mice (Fig. 6A). The activation of executioner caspases,
especially caspases 3 and 7, is a biochemical hallmark of apoptosis.34 Therefore, to further
confirm that hepatocyte apoptosis occurs in wt animals following BDL, we performed
immunohistochemistry for activated caspases 3/7. Immunoreactive product was readily
identified in liver tissues from wt mice following BDL but not in sham-operated controls (Fig.
6B). Consistent with the TUNEL assay, BDL wt animals demonstrated an 11-fold increase in
the number of caspase 3/7–positive hepatocytes versus sham-operated controls (Fig. 6B).
Caspase 3/7–positive cells were also reduced in TRAILí/í BDL animals as compared to wt
animals, with an intermediate number of positive cells in TRAIL+/í animals. Taken together,
these data are consistent with TRAIL-potentiated apoptosis in BDL mice.
TRAIL Contributes to Liver Injury in the BDL Mouse

NIH-PA Author Manuscript

To determine if TRAIL-mediated hepatocyte apoptosis translates into significant
hepatotoxicity, histopatho-logical examination of liver specimens was performed along with
determination of serum ALT values. Histopathological examination of liver specimens from
7-day BDL wt mice displayed severe cholestatic hepatitis with widespread bile infarctions,
bile ductular proliferation, portal edema, and hepatocellular damage. Liver damage was
reduced in specimens from TRAIL+/í and TRAILí/í animals following 7 days of BDL (Fig.
7A). In addition, bile infarctions were also less evident in BDL TRAIL+/í and TRAILí/í mice
(Fig. 7B). A marked reduction in serum ALT values in TRAIL+/í and TRAILí/í animals as
compared to wt mice was also observed 7 days following BDL (Fig. 7C). Differences in
hepatocyte apoptosis and liver injury could not be ascribed to alterations in cholestasis because
total bilirubin determinations (Fig. 7D) as well as total bile acid concentrations (Fig. 7E) in
BDL mice were almost identical, indicating similar cholestatic effects of BDL between groups
of animals. The decrease in liver injury in the TRAILí/í mice was due to a reduction in
hepatocyte apoptosis. Thus, these data suggest that the death ligand TRAIL is hepatotoxic in
animals with obstructive cholestasis.
TRAIL Cytotoxicity Is Associated with Lysosomal Release of Cathepsin B
We have recently reported that TRAIL cytotoxicity in cultured human hepatoma cell lines is
associated with a redistribution of cathepsin B from lysosomes into the cytosol.35 To ascertain
if this also occurs in vivo following BDL, liver sections were examined by coimmuno
Hepatology. Author manuscript; available in PMC 2008 October 20.
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Markers of Hepatic Fibrogenesis Are Diminished in TRAILí/í Animals Following BDL for 14
Days

NIH-PA Author Manuscript

fluorescence for cathepsin B and LAMP-1 (a lysosomal-associated membrane protein and a
marker for lysosomes). Under basal conditions in sham-operated controls, cells displayed a
punctate pattern for cathepsin B and LAMP-1 consistent with lysosomal cathepsin B
localization. However, following 7 days of BDL, hepatocytes of wt mice revealed a diffuse
fluorescence pattern for cathepsin B suggesting a redistribution of cathepsin B from lysosomes
into the cytosol, whereas the fluorescence pattern for LAMP-1 remained punctate (Fig. 8A).
In contrast, cells from BDL TRAIL+/í and TRAILí/í animals displayed a mixed fluorescence
pattern for cathepsin B, with the majority of cells examined displaying a punctate pattern of
fluorescence (Fig. 8A). The percentage of cells with a diffuse distribution of cathepsin B was
increased in wt mice as compared to TRAIL+/í and TRAILí/í BDL mice (Fig. 8B). These data
demonstrate that following BDL, cathepsin B undergoes a cellular redistribution from
lysosomes into the cytosol by a TRAIL-dependent process.

If the reduction of liver injury in TRAILí/í mice is significant, it should also translate into
reduced hepatic fibrosis, a sequela of liver damage. Because stellate cells are the principal
hepatic cell type responsible for collagen deposition in the liver,36 we next quantified
transcripts for stellate cell activation by rt-PCR. After 14 days of BDL, mRNA for Į-SMA, a
cardinal marker for stellate cell activation, was increased 11-fold in wt mice as compared to
sham-operated mice. More importantly, the transcript for Į-SMA was reduced in TRAILí/í
animals (Fig. 9A). Consistent with the mRNA data, Į-SMA immunoreactivity was also
increased in the sinusoids of BDL wt mice but reduced in BDL TRAIL+/í mice (Fig. 9B). To
ascertain if stellate cell activation was also associated with enhanced hepatic fibrogenesis,
mRNA for hepatic collagen 1Į (I) was quantified. Collagen 1Į (I) mRNA expression was
increased 3-fold in wt mice versus TRAILí/í mice after BDL (Fig. 9C). Hepatic collagen
protein deposition was identified in liver specimens by Sirius red staining (Fig. 9D) and
subjected to quantitative morphometry.26 Collagen staining by Sirius red was increased 4-fold
in wt BDL mice versus TRAILí/í BDL mice (Fig. 9D). Collectively, these data suggest that
in wt animals following BDL for 14 days, hepatic stellate cell activation and hepatic
fibrogenesis are attenuated in TRAILí/í mice, likely secondary to the reduced liver injury in
these animals.
Survival of TRAILí/í Animals Is Enhanced Following BDL

NIH-PA Author Manuscript

Given that liver injury and fibrogenesis are significantly reduced in TRAILí/í animals, we
reasoned that animal survival should also be enhanced. Therefore, in our final series of studies,
we examined overall animal survival in BDL mice. By day 14 after BDL, 80% of TRAILí/í
animals were still alive compared to only 20% in the wt animal group (Fig. 10). Taken together,
these studies demonstrate that during cholestasis, deficiency of TRAIL exerts an important
prosurvival effect. Given that the TRAIL deletion is not liver-specific, the organ-specific
effects responsible for enhanced animal survival cannot be specifically delineated. However,
as germ line TRAIL deletion reduces liver injury, hepato-protection likely, in part, contributes
to the improved animal survival.

Discussion
Cholestatic liver injury is an exceedingly complex pathophysiologic syndrome. We have
previously implicated a role for the innate immune system in cholestatic liver injury by Kupffer
cells.20 The current study extends these observations by elucidating a role for NK/NKT cells
in this process. NK/NKT cell–dependent liver injury was TRAIL-dependent. Enhanced TRAIL
expression is a special feature of hepatic NK cells due to their unique responsiveness to
interleukin-2 as compared to peripheral NK cells.19 Although NK cells can induce cell death
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by both perforin/granzyme B–dependent and TRAIL-dependent mechanisms,37 hepatocytes
richly express the granzyme B inhibitors, proteinase inhibitor 9 and serine proteinase inhibitor
6, which limit injury by the perforin/granzyme B mechanism.38 Therefore, our results
demonstrating TRAIL-dependent and NK/NKT cell–dependent liver injury in the BDL murine
liver are consistent with the current concepts regarding NK cells in liver pathobiology. These
data are also consistent with the emerging concept that the liver is an integral organ of the
innate immune system39,40 and is often activated with deleterious consequences during
pathophysiologic disturbances.
Unexpectedly, we observed an accumulation of fat in the livers of wt BDL mice after depletion
of NK cells (Fig. 1C). Prior studies have shown, however, that in genetically obese, leptindeficient mice, hepatic NK cells are depleted. This cellular depletion was associated with
steatohepatitis, reduced hepatic expression of anti-inflammatory cytokines, and increased
activity of pro-inflammatory cytokines.41,42 The steatosis observed by depletion of NK 1.1–
positive NK/NKT cells in our study is therefore consistent with previous studies suggesting
that this cellular population negatively regulates neutral fat deposition in hepatocytes. It is very
unlikely that fat could be an explanation for the resistance of the BDL to TRAIL-mediated
injury as fat actually sensitizes hepatocytes to TRAIL.16,43

NIH-PA Author Manuscript

Genetic deletion of TRAIL reduced hepatocyte apoptosis in the BDL mouse. Although TRAIL
is nontoxic to normal hepatocytes,44 it is cytotoxic to transformed,45 virally infected,46 free
fatty acid–treated,16,43 and bile acid–treated hepatocytes.11 Therefore, TRAIL can directly
induce hepatocyte cytotoxicity in disease states. During cholestasis, hepatocytes are likely
sensitized to TRAIL because of bile acid–mediated up-regulation of the cognate receptor
TRAIL-receptor 2.11,47 TRAIL’s cytotoxic effect in cholestasis could also be by an indirect
rather than direct mechanism. TRAIL can potentiate Fas-induced liver injury by activating
JNK,17 and Fas deletion also reduces hepatic injury and fibrosis in the BDL mouse.26 Taken
together, these observations suggest potential cooperativity between the two death receptors
in the BDL mouse. This cooperativity is especially likely as NK cells express both Fas ligand
and TRAIL48 and likely engage their respective receptors on the target hepatocyte membrane.
Whether its cytotoxicity is direct or indirect, TRAIL appears to play an integral role in
cholestatic liver injury.
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We have previously implicated cathepsin B as a mediator of liver injury and fibrogenesis in
the BDL mouse.49 Indeed, mice genetically deficient for cathepsin B have reduced liver injury
and fibrosis. However, in those studies, neither the release of cathepsin B from lysosomes into
the cytosol nor the mechanisms for lysosomal permeabilization were examined. The current
studies, therefore, extend the prior observations by demonstrating a redistribution of cathepsin
B from a lysosomal compartment into the cytosol of hepatocytes following BDL. This
phenomenon was absent in TRAIL-deficient BDL mice, and this observation is consistent with
TRAIL-mediated lysosomal permeabilization in vitro.35 Given that Fas stimulation does not
induce permeabilization of liver lysosomes,50 release of cathepsin B from lysosomes into the
cytosol appears to be TRAIL-mediated.
We and others have previously suggested that TRAIL is cytotoxic for activated stellate cells.
51,52 Solely on the basis of these observations, genetic deletion of TRAIL would have been
predicted to enhance hepatic fibrosis. In contrast, we observed reduced hepatic fibrosis in
TRAILí/í BDL mice. The reduced hepatic fibrosis is best explained by the observed reduction
in hepatocyte apoptosis in TRAIL-deficient mice. Hepatic fibrogenesis is mediated by
activated stellate cells, which are the principal source of collagen I in the liver. Apoptosis can
activate this cell type by two recognized mechanisms involving phagocytosis of apoptotic
bodies. These remnants of the apoptotic process can be phagocytosed by Kupffer and/or stellate
cells.4,20 This phagocytotic process activates both cell types. Kupffer cell engulfment of
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apoptotic bodies results in expression of transforming growth factor ȕ, a profibrogenic cytokine
that activates stellate cells by a paracrine mechanism.36 Alternatively, phagocytosis of
apoptotic bodies directly by stellate cells also results in their expression of transforming growth
factor ȕ, which, in a cell autonomous manner, may drive activation by an autocrine process.
53 Either cellular mechanism could account for the reduction of hepatic fibrosis by apoptosis
inhibition in the current study.
In summary, TRAIL deletion attenuates liver injury and improves animal survival in the BDL
mouse. These data are consistent with a critical role for TRAIL as a mediator of hepatic damage
during cholestasis in preclinical models. Mechanisms to disrupt TRAIL signaling pathways,
such as modulating NK/NKT cell activation, could prove to be therapeutic in human cholestatic
liver diseases. These data also suggest TRAIL agonists should be used with caution during
cholestasis, as TRAIL may prove to be hepatotoxic in this syndrome.
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Į-SMA, Į-smooth muscle actin
ALT, alanine aminotransferase
ANOVA, analysis of variance
BDL, bile duct ligation/bile duct–ligated
bp, base pair
cDNA, complementary DNA
DAB, 3,3'-diaminobenzidine
DR5, death receptor 5
GAPDH, glyceraldehyde 3-phosphate dehydrogenase
H&E, hematoxylin and eosin
hpf, high-power field
IgG, immunoglobulin G
JNK, c-Jun-N-terminal kinase
LAMP, lysosome-associated membrane protein
mRNA, messenger RNA
MULT-1, murine UL16-binding protein-like transcript 1
NK, natural killer
NKT, natural killer T
PCR, polymerase chain reaction
RAE-1, retinoic acid early inducible gene 1
rt-PCR, real time–polymerase chain reaction
SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis
TRAIL, tumor necrosis factor–related apoptosis-inducing ligand
TRAILí/í, TRAIL homozygote
TRAIL+/í, TRAIL heterozygote
TRAIL-R2, tumor necrosis factor–related apoptosis-inducing ligand receptor 2
Tris, trishydroxymethylaminomethane
TUNEL, terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling
wt, wild-type
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Fig. 1.
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Hepatic NK 1.1–positive cells are increased following BDL. (A) Immunohistochemistry for
NK 1.1 cells demonstrated an almost identical increase of NK 1.1–positive cells in the BDL
livers of wt, TRAIL+/í, and TRAILí/í animals (magnification by light microscopy 60X).
Quantitation of NK 1.1–positive cells demonstrated a significant increase in BDL mice as
compared to sham-operated mice. *P < 0.01 by ANOVA. Data from five independent animals
per group are expressed as the mean ± standard error. (B) Quantitative rt-PCR demonstrated
almost equal mRNA expression levels for NK 1.1 in the livers of all three genotypes following
BDL. *P < 0.01 by ANOVA for BDL mice versus sham-operated wt mice. (C)
Immunohistochemistry for NK 1.1 cells demonstrated an almost identical increase of these cell
types in wt and IgG-treated wt animals following BDL. wt mice following BDL and NK cell
depletion displayed fewer hepatic NK cells along with accumulation of fat in the liver.
Quantitation of NK 1.1 cells demonstrated a significant decrease in BDL wt mice after NK cell
depletion as compared to BDL wt mice treated with control, isotype-identical IgG. Data from
five independent animals per group are expressed as the mean ± standard error. *P < 0.05 by
ANOVA. (D) Quantitative rt-PCR demonstrated decreased mRNA expression levels for NK
1.1 cells in the livers of NK cell-depleted wt mice as compared to control IgG-treated wt mice
following BDL.
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Liver injury in the BDL mouse is NK/NKT cell-dependent. Representative photomicrographs
of conventional H&E-stained liver sections (magnification 40X) are shown. (A) Liver
specimens of wt BDL mice displayed significant and extensive hepatocyte injury with bile
infarcts (marked with asterisks), bile duct proliferation, and portal edema. BDL-induced liver
injury was reduced in wt animals upon treatment with the anti-NK 1.1 antibody and was absent
in liver sections of sham-operated control mice. Bile infarcts (confluent foci of hepatocyte
feathery degeneration caused by bile acid cytotoxicity) were quantified and were also less
evident in BDL wt mice treated with the anti-NK 1.1 antibody. (B) Serum ALT values were
measured 7 days after BDL and demonstrated a significant decrease in BDL wt mice after
depletion of NK 1.1–positive cells from the liver. Data are from five independent animals and
are expressed as the mean ± standard error. *P < 0.05 by ANOVA.
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Hepatocytes up-regulate stress ligands following BDL. Quantitative rt-PCR demonstrated
increased hepatic mRNA expression levels of the stress ligands H60, MULT-1, and pan-RAE-1
in hepatocytes of 3-day BDL wt mice versus sham-operated control mice. Data are from five
independent animals and are expressed as the mean ± standard error. *P < 0.05 by ANOVA.
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NK/NKT cells are the predominant source of increased TRAIL in the BDL liver. Quantitative
rt-PCR demonstrated decreased mRNA expression levels for TRAIL in the livers of BDL wt
mice after depletion of NK 1.1–positive cells. Data points represent experiments from five
independent animals, and bars are expressed as the mean ± standard error. *P < 0.05 by
ANOVA.
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Fig. 5.

Protein expression of apoptosis effectors is similar between the different mouse genotypes.
Aliquots of 50 µg of hepatic protein were subjected to SDS-PAGE and western blot analyses.
The depicted blots are representative of five separate experiments, and a representative
immunoblot from each animal group is shown. (A) Western blot analyses were performed for
several apoptosis-related proteins in wt and TRAILí/í animals under basal conditions. ȖTubulin was used as the control for protein loading. (B) No alterations in the expression levels
of the Fas receptor and ligand were observed in wt, TRAIL+/í, and TRAILí/í mice following
BDL.
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Fig. 6.

Hepatocyte apoptosis is reduced in TRAILí/í mice following BDL. (A) The number of
TUNEL-positive cells (marked with arrows) was quantitated and expressed as apoptotic cells/
10 high-power fields (hpf). Data are from five independent animals per group and are expressed
as the mean ± standard error. *P < 0.05 by ANOVA for wt mice versus TRAILí/í mice
following BDL. (B) Immunohistochemistry for the neo-epitopes of caspases 3/7 was performed
(arrows indicate caspase 3/7–positive cells). Data points represent experiments from five
independent animals, and bars are expressed as the mean ± standard error. *P < 0.05 by
ANOVA for wt mice versus TRAILí/í mice following BDL.
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Liver injury is attenuated in TRAIL-deficient mice. wt, TRAIL+/í, and TRAILí/í mice were
subjected to common BDL. On day 7 post-surgery, mice were sacrificed to obtain liver and
serum samples for histological examination and determination of ALT values. (A)
Representative photomicrographs of conventional H&E-stained liver sections (magnification
40X) are shown. Liver specimens of wt BDL mice displayed significant and extensive
hepatocyte injury with bile infarcts (marked with asterisks). BDL-induced liver injury was
reduced in TRAIL-deficient animals and was absent in liver sections of sham-operated control
mice. (B) Bile infarcts were quantified in BDL wt and TRAIL-deficient mice. (C) Serum ALT
values were measured 7 days after BDL. Data are from five independent animals and are
expressed as the mean ± standard error. *P < 0.05 by ANOVA for wt mice versus TRAILí/í
mice following BDL. (D) Serum total bilirubin determinations were quantified 7 days after
BDL. *P < 0.01 by ANOVA for BDL mice versus sham-operated mice. (E) Total serum bile
acid concentrations were identical between BDL wt and TRAILí/í animals. Data are from five
independent animals and are expressed as the mean ± standard error. *P < 0.01 by ANOVA
for BDL wt mice versus sham-operated wt mice.
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Fig. 8.

Lysosomal release of cathepsin B 7 days following BDL. (A) One week after the surgical
procedure, liver tissue was obtained and analyzed by co-immunofluorescence for subcellular
distribution of cathepsin B and LAMP-1. Liver tissue was viewed and imaged for punctate or
diffuse appearance of the antigens by confocal microscopy using digital image analysis.(B)
Quantitation of hepatocytes presenting a diffuse distribution of cathepsin B. Data are from 5
independent animals and are expressed as the mean ± standard error. *P < 0.05 by ANOVA.
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Fig. 9.
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Hepatic fibrosis is reduced in TRAILí/í animals following BDL. (A) Mice underwent BDL,
and 14 days after the surgical procedure, liver tissue was procured to isolate total hepatic RNA.
Į-SMA and collagen 1Į (I) mRNA expression, markers for stellate cell activation and hepatic
fibrogenesis, were quantified by rt-PCR. Data were obtained from five independent animals
and are expressed as the mean ± standard error. *P < 0.05 by ANOVA. (B) Photomicrographs
after immunohistochemistry for Į-SMA following BDL of 14 days are depicted. (C)
Expression of collagen 1Į (I) mRNA was quantified by rt-PCR 14 days after BDL (n = 5 for
each group). *P < 0.05 by ANOVA. (D) Sirius red staining, a chemical stain of collagen
deposition in the liver, was performed 14 days after BDL. Collagen fibers stained with Sirius
red were quantitated using digital image analysis. Representative photomicrographs of liver
sections are depicted (magnification by light microscopy 40X). Sirius red staining was
quantitatively greater in wt mice than in TRAILí/í mice following BDL for 14 days (n = 5 for
each group). *P < 0.05 by ANOVA.
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Animal survival following BDL is enhanced in TRAILí/í animals. Overall animal survival is
improved in BDL TRAILí/í mice as compared to wt animals. Initially, on day 4 after BDL,
80% of TRAILí/í animals were alive, whereas 100% of the wt mice survived cholestatic liver
injury. However, on day 13 after BDL, 80% of TRAILí/í animals were still alive compared
to only 20% in the wt animal group.
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